Shares of aTyr Pharma Inc (NASDAQ:LIFE) fell 5.7% during trading on Tuesday . The stock traded as low as $0.45 and last traded at $0.50. 698,461 shares were traded during mid-day trading, an increase of 77% from the average session volume of 394,179 shares. The stock had previously closed at $0.53.
Several research firms have commented on LIFE. ValuEngine downgraded shares of aTyr Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. Zacks Investment Research cut shares of aTyr Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, January 16th. Finally, William Blair restated a “market perform” rating on shares of aTyr Pharma in a research note on Tuesday, March 26th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $1.01.
The company has a debt-to-equity ratio of 0.25, a quick ratio of 4.69 and a current ratio of 4.69. The company has a market capitalization of $17.14 million, a price-to-earnings ratio of -0.42 and a beta of 2.51.
aTyr Pharma (NASDAQ:LIFE) last issued its quarterly earnings data on Monday, May 13th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.05.
An institutional investor recently raised its position in aTyr Pharma stock. Renaissance Technologies LLC lifted its position in aTyr Pharma Inc (NASDAQ:LIFE) by 12.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,540,559 shares of the biotechnology company’s stock after buying an additional 172,600 shares during the quarter. Renaissance Technologies LLC owned about 4.22% of aTyr Pharma worth $847,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 29.20% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.thelincolnianonline.com/2019/05/16/atyr-pharma-life-trading-down-5-7.html.
aTyr Pharma Company Profile (NASDAQ:LIFE)
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD.
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.